Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

70.900
+0.6500.93%
Volume:781.85K
Turnover:54.79M
Market Cap:470.56B
PE:62.46
High:70.900
Open:70.000
Low:69.200
Close:70.250
52wk High:95.200
52wk Low:52.500
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:0.77
T/O Rate:0.30%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.135
ROE:14.34%
ROA:8.37%
PB:6.97
PE(LYR):62.46
PS:13.38

Loading ...

Hengrui Pharma's Innovative Drug HRS-5346 for Elevated Lipoprotein(a) Levels Added to Breakthrough Therapy List

Deep News
·
Feb 12

Small Nucleic Acids Reshape Weight Loss Paradigm with INHBE and ALK7 Targets Showing Initial Validation

Stock News
·
Feb 12

Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug

MT Newswires Live
·
Feb 11

HENGRUI PHARMA's New Antibody Drug Application for Injectable SHR-A1811 Accepted and Granted Priority Review

Stock News
·
Feb 10

Hengrui Pharma's HRS-4642 Injection Granted Breakthrough Therapy Designation

Stock News
·
Feb 06

AH Share Premium Rankings as of February 5th

Stock News
·
Feb 05

HENGRUI PHARMA (01276) Allocates 9.317 Million Yuan for 165,000 A-Share Buyback on February 4

Stock News
·
Feb 04

Hengrui Pharma: Resubmitted Camrelizumab Injection Combination Therapy Application Accepted by FDA

Deep News
·
Feb 03

Hengrui Pharma (600276) Announces Postponement of Board Re-Election

Bulletin Express
·
Feb 02

Jiangsu Hengrui Pharmaceuticals (600276) Announces Share Repurchase and Updated Share Structure

Bulletin Express
·
Feb 02

Hengrui Pharma (600276.SH) Resubmits BLA for Camrelizumab Injection, Accepted by FDA

Stock News
·
Feb 02

HENGRUI PHARMA (01276): Marketing Authorization Application for HR20013 Injection Accepted by NMPA

Stock News
·
Jan 30

Valuation Ranges of Biopharma: Insights from Innovent Biologics, Hengrui Pharmaceuticals, and BeiGene

Deep News
·
Jan 30

Zhixintong A-H Statistics | January 30th

Stock News
·
Jan 30

Hengrui Pharma (01276) Receives Clinical Trial Approval for HRS-7535 Tablets

Stock News
·
Jan 29

HENGRUI PHARMA (01276) Marketing Application for New Indication of Innovative Drug Camrelizumab and Apatinib Combination Accepted

Stock News
·
Jan 29

Jiangsu Hengrui Pharmaceuticals (600276) Announces Share Repurchase and Updated Share Figures

Bulletin Express
·
Jan 29

Hengrui Pharma (01276) Repurchases 371,600 A-Shares for RMB 21.074 Million on January 29

Stock News
·
Jan 29

Hengrui Pharma (01276) Completes Cumulative Share Buyback of 9.0737 Million Shares by January 27

Stock News
·
Jan 27

ZhTong A-H Statistics | January 27

Stock News
·
Jan 27